TRVN:OTCMKTS
Trevena Inc
$0,066
0,00%
(0,00) 1G
12 Eki, 14:57:26 GMT-4 · USD
search
Tüm semboller
| Sembol | Fiyat | DeÄŸiÅŸiklik | DeÄŸiÅŸiklik % |
|---|
insights_autoTRVN ile ilgili en önemli analizler oluşturuluyor...
Piy. deÄŸ.
57,01Â B
Ort. hacim
210,00
Ä°ÅŸlem Hacmi
23,00
52 haftalık en yüksek
$1,50
52 haftalık en düşük
$0,00
Beta
1,07
Tedavüldeki hisse senedi sayısı
864,00Â B
Çalışan sayısı
23
Piy. deÄŸ.
57,01Â B
Ort. hacim
210,00
Ä°ÅŸlem Hacmi
23,00
52 haftalık en yüksek
$1,50
52 haftalık en düşük
$0,00
Beta
1,07
Tedavüldeki hisse senedi sayısı
864,00Â B
Çalışan sayısı
23
Haberler
Web kaynaklarından ve haber iş ortaklarından
GlobeNewswire
·
12 dakika önce
FBS Global Regains Compliance with Nasdaq Minimum Bid Price Requirement
Stock Titan
·
16 dakika önce
After 30 business days below $1, AGM Group (Nasdaq: AGMH) gets time to regain compliance.
Investor's Business Daily
·
8 dakika önce
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
AP News
·
22 dakika önce
How major US stock indexes fared Tuesday 10/13/2026
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Trevena Inc hakkında
CEO-
Çalışan Sayısı23
KuruluÅŸ Tarihi2007
Genel MerkezAtlanta, Georgia, Amerika BirleÅŸik Devletleri
Sektör-
Web Sitesitrevena.com